Logo image of CFRX

CONTRAFECT CORP (CFRX) Stock Fundamental Analysis

USA - NASDAQ:CFRX - US2123264093 - Common Stock

0.2318 USD
+0.01 (+2.84%)
Last: 11/8/2023, 8:26:06 PM
0.171 USD
-0.06 (-26.23%)
After Hours: 11/8/2023, 8:26:06 PM
Fundamental Rating

1

Taking everything into account, CFRX scores 1 out of 10 in our fundamental rating. CFRX was compared to 534 industry peers in the Biotechnology industry. CFRX may be in some trouble as it scores bad on both profitability and health. CFRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CFRX has reported negative net income.
In the past year CFRX has reported a negative cash flow from operations.
CFRX had negative earnings in each of the past 5 years.
In the past 5 years CFRX always reported negative operating cash flow.
CFRX Yearly Net Income VS EBIT VS OCF VS FCFCFRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The Return On Assets of CFRX (-186.23%) is worse than 91.87% of its industry peers.
Industry RankSector Rank
ROA -186.23%
ROE N/A
ROIC N/A
ROA(3y)-133.5%
ROA(5y)-110.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CFRX Yearly ROA, ROE, ROICCFRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5K 10K 15K 20K 25K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CFRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CFRX Yearly Profit, Operating, Gross MarginsCFRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

1

2. Health

2.1 Basic Checks

CFRX has more shares outstanding than it did 1 year ago.
CFRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CFRX Yearly Shares OutstandingCFRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 100K 200K 300K 400K 500K
CFRX Yearly Total Debt VS Total AssetsCFRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -31.04, we must say that CFRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -31.04, CFRX is doing worse than 94.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.04
ROIC/WACCN/A
WACCN/A
CFRX Yearly LT Debt VS Equity VS FCFCFRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.00 indicates that CFRX should not have too much problems paying its short term obligations.
The Current ratio of CFRX (1.00) is worse than 90.38% of its industry peers.
A Quick Ratio of 1.00 indicates that CFRX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.00, CFRX is doing worse than 89.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 1
CFRX Yearly Current Assets VS Current LiabilitesCFRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

CFRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.60%, which is quite impressive.
EPS 1Y (TTM)61.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CFRX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.78% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.87%
EPS Next 2Y40.94%
EPS Next 3Y25.78%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CFRX Yearly EPS VS EstimatesCFRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CFRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CFRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CFRX Price Earnings VS Forward Price EarningsCFRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CFRX Per share dataCFRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30

4.3 Compensation for Growth

CFRX's earnings are expected to grow with 25.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.94%
EPS Next 3Y25.78%

More info and screens

0

5. Dividend

5.1 Amount

CFRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTRAFECT CORP

NASDAQ:CFRX (11/8/2023, 8:26:06 PM)

After market: 0.171 -0.06 (-26.23%)

0.2318

+0.01 (+2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/bmo
Earnings (Next)03-29 2024-03-29/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners192.77%
Ins Owner Change0%
Market Cap1.27M
Revenue(TTM)N/A
Net Income(TTM)-35850000
Analysts82.86
Price Target5.1 (2100.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.34%
Min EPS beat(2)-5.08%
Max EPS beat(2)93.75%
EPS beat(4)3
Avg EPS beat(4)33.11%
Min EPS beat(4)-5.08%
Max EPS beat(4)93.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)65.63%
EPS NY rev (1m)0%
EPS NY rev (3m)49.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-37.17
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-6.69
FCFYN/A
OCF(TTM)-6.67
OCFYN/A
SpS0
BVpS-0.2
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -186.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-133.5%
ROA(5y)-110.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1
Quick Ratio 1
Altman-Z -31.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)13.33%
Cap/Depr(5y)27.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.73%
EPS Next Y96.87%
EPS Next 2Y40.94%
EPS Next 3Y25.78%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.16%
OCF growth 3YN/A
OCF growth 5YN/A

CONTRAFECT CORP / CFRX FAQ

What is the fundamental rating for CFRX stock?

ChartMill assigns a fundamental rating of 1 / 10 to CFRX.


What is the valuation status for CFRX stock?

ChartMill assigns a valuation rating of 1 / 10 to CONTRAFECT CORP (CFRX). This can be considered as Overvalued.


Can you provide the profitability details for CONTRAFECT CORP?

CONTRAFECT CORP (CFRX) has a profitability rating of 0 / 10.


What is the financial health of CONTRAFECT CORP (CFRX) stock?

The financial health rating of CONTRAFECT CORP (CFRX) is 1 / 10.